Oregon § 689.800 Opioid overdose; treatment; administration of short-acting opioid antagonist; liability; rules

Oregon Statutes

§ 689.800 — Opioid overdose; treatment; administration of short-acting opioid antagonist; liability; rules

Oregon § 689.800

Vol.17

Title 52Occupations and Professions

Ch. 689Pharmacists; Drug Outlets; Drug Sales

This text of Oregon § 689.800 (Opioid overdose; treatment; administration of short-acting opioid antagonist; liability; rules) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Or. Rev. Stat. § 689.800 (2026).

Text

(1)As used in this section:

(a)“Kit” means a package of one or more doses of a short-acting opioid antagonist and the necessary medical supplies to administer the short-acting opioid antagonist.

(b)“Opioid” means a natural, synthetic or semisynthetic chemical that interacts with opioid receptors on nerve cells in the body and brain to reduce the intensity of pain signals and feelings of pain.

(c)“Opioid overdose” means a medical condition that causes depressed consciousness, depressed respiratory function or the impairment of vital bodily functions as a result of ingesting opioids.

(d)“Short-acting opioid antagonist” means any short-acting drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose.

(2)Notwithstanding any

Free access — add to your briefcase to read the full text and ask questions with AI

(1) As used in this section:
(a) “Kit” means a package of one or more doses of a short-acting opioid antagonist and the necessary medical supplies to administer the short-acting opioid antagonist.
(b) “Opioid” means a natural, synthetic or semisynthetic chemical that interacts with opioid receptors on nerve cells in the body and brain to reduce the intensity of pain signals and feelings of pain.
(c) “Opioid overdose” means a medical condition that causes depressed consciousness, depressed respiratory function or the impairment of vital bodily functions as a result of ingesting opioids.
(d) “Short-acting opioid antagonist” means any short-acting drug approved by the United States Food and Drug Administration for the complete or partial reversal of an opioid overdose.
(2) Notwithstanding any other provision of law, a pharmacy, a health care professional, a pharmacist with prescription and dispensing privileges, a law enforcement officer, a firefighter, an emergency medical services provider or any other person designated by the State Board of Pharmacy by rule may:
(a) Distribute and administer a short-acting opioid antagonist and distribute the necessary medical supplies to administer the short-acting opioid antagonist;
(b) Distribute multiple kits to:
(A) An individual who has experienced an opioid overdose or is likely to experience an opioid overdose;
(B) Family members of an individual described in subparagraph (A) of this paragraph; and
(C) Any other individual who requests one or more kits; and
(c) Distribute multiple kits to social service agencies under ORS 689.804 or to other persons who work with individuals who have experienced an opioid overdose. The social services agencies or other persons may redistribute the kits to individuals likely to experience an opioid overdose or to family members of the individuals.
(3)(a) A person acting in good faith, if the act does not constitute wanton misconduct, is immune from criminal and civil liability for any act or omission of an act committed during the course of distributing and administering a short-acting opioid antagonist and distributing the necessary medical supplies to administer the short-acting opioid antagonist under this section.
(b) A person acting in good faith is immune from criminal and civil liability for the person’s failure or refusal to distribute or administer a short-acting opioid antagonist or distribute the necessary medical supplies to administer a short-acting opioid antagonist under this section, if the person’s failure or refusal does not constitute wanton misconduct.